This is a regulatory disclosure made by Dr. Reddy's Laboratories Ltd. pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The company intimated that a meeting of its Board of Directors is scheduled to be held on Friday, October 23, 2026. The primary agenda for this meeting is to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ending on September 30, 2026 (Q2 FY2027).
Concurrently, pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, the company announced the closure of the trading window for dealing in its securities. The window will be closed from September 24, 2026, to October 25, 2026 (both days inclusive). This is a standard procedure to prevent insider trading around the period of financial results preparation and declaration.
The disclosure was addressed to the National Stock Exchange of India Ltd., BSE Limited, New York Stock Exchange Inc., and NSE IFSC Ltd. It was signed by K Randhir Singh, who holds the positions of Company Secretary, Compliance Officer, and Head-CSR.